Clinical Trial: Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801248) titled 'Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)' on Aug. 28.

Brief Summary: The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD) following allogenic hematopoietic stem cell transplantation (HSCT).

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Acute Skin Graft Versus Host Disease (GVHD)

Intervention: DRUG: Ruxolitinib 1.5% cream

Ruxolitinib is a Janus Kinase (JAK) 1/2 inhibitor. JAKs are intracellular tyrosine kinases that play an important role in the development and function of immun...